CODX Co-Diagnostics, Inc.
Price Chart
Executive Summary
Co-Diagnostics filed a universal shelf registration statement to offer up to $150M in securities (common, preferred, debt, warrants, units, rights) from time to time. With a market cap of only $7M, this shelf represents over 20x the company's current equity value, signaling extreme potential dilution. The company has no committed offerings yet, but the filing provides maximum flexibility to raise capital as needed.
Key Financial Metrics
Actionable Insight
The extreme size of this shelf relative to market cap creates massive overhang. Monitor for any prospectus supplement indicating an actual takedown — even a small percentage of the shelf would be highly dilutive. The company's failed FDA submission and ongoing cash needs suggest a capital raise is likely imminent. Short sellers should watch for accelerated offerings.
Key Facts
- Shelf registration allows up to $150,000,000 in securities — over 20x the current $7M market cap
- Stock price was $1.90 per share as of May 11, 2026
- Only 2,095,031 shares outstanding as of December 31, 2025
- Company voluntarily withdrew its FDA 510(k) submission for the Co-Dx PCR COVID-19 test in 2024
- No binding agreements or commitments for any specific offering at this time
- Proceeds intended for working capital, sales/marketing, capital expenditures, and product development
Financial Impact
Up to $150,000,000 in potential dilution against a $7M market cap — maximum dilution could exceed 95% of existing equity
Risk Factors
- Extreme dilution risk — shelf is 20x current market cap
- Company has no committed revenue from its PCR platform (FDA submission withdrawn)
- Potential for distressed capital raise given limited cash runway
- Stock already trading near $1.90 — any offering could push price below Nasdaq listing requirements
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-022504 |
| Exhibit: ex4-1.htm | 0001493152-26-022504 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
today
|
8-K
| $2.86 awaiting T+5 | awaiting T+5 | — | $3.83 (−33.75%) |
|
May 18, 2026
3d ago
|
EFFECT
| — | awaiting T+5 | — | — |
|
May 14, 2026
6d ago
|
8-K
| $1.64 awaiting T+5 | awaiting T+5 | — | $3.83 (−133.53%) |
|
May 12, 2026
8d ago
|
S-3
| $1.60 $1.97 | ▼ −23.13% | ▼ −24.28% | $3.83 (−139.37%) |
|
Mar 31, 2026
7w ago
|
8-K
| $1.62 $1.44 | ▲ +11.11% | ▲ +14.88% | $3.83 (−136.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access